Literature DB >> 27157252

Genomewide profiling of copy-number alteration in monoclonal gammopathy of undetermined significance.

Aneta Mikulasova1,2,3,4, Jan Smetana1,2, Marketa Wayhelova1,2, Helena Janyskova1, Viera Sandecka5, Zuzana Kufova4,6, Martina Almasi7, Jiri Jarkovsky8, Evzen Gregora9, Petr Kessler10, Marek Wrobel11, Brian A Walker12, Christopher P Wardell12,13, Gareth J Morgan12, Roman Hajek4,6, Petr Kuglik1,2,3.   

Abstract

Monoclonal gammopathy of undetermined significance (MGUS) is a benign condition with an approximate 1% annual risk of symptomatic plasma cell disorder development, mostly to multiple myeloma (MM). We performed genomewide screening of copy-number alterations (CNAs) in 90 MGUS and 33 MM patients using high-density DNA microarrays. We identified CNAs in a smaller proportion of MGUS (65.6%) than in MM (100.0%, P = 1.31 × 10-5 ) and showed median number of CNAs is lower in MGUS (3, range 0-22) than in MM (13, range 4-38, P = 1.82 × 10-10 ). In the MGUS cohort, the most frequent losses were located at 1p (5.6%), 6q (6.7%), 13q (30.0%), 14q (14.4%), 16q (8.9%), 21q (5.6%), and gains at 1q (23.3%), 2p (6.7%), 6p (13.3%), and Xq (7.8%). Hyperdiploidy was detected in 38.9% of MGUS cases, and the most frequent whole chromosome gains were 3 (25.6%), 5 (23.3%), 9 (37.8%), 15 (23.3%), and 19 (32.2%). We also identified CNAs such as 1p, 6q, 8p, 12p, 13q, 16q losses, 1q gain and hypodiploidy, which are potentially associated with an adverse prognosis in MGUS. In summary, we showed that MGUS is similar to MM in that it is a genetically heterogeneous disorder, but overall cytogenetic instability is lower than in MM, which confirms that genetic abnormalities play important role in monoclonal gammopathies.
© 2016 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  DNA copy-number changes; DNA microarrays; monoclonal gammopathies; prognosis

Mesh:

Year:  2016        PMID: 27157252     DOI: 10.1111/ejh.12774

Source DB:  PubMed          Journal:  Eur J Haematol        ISSN: 0902-4441            Impact factor:   2.997


  13 in total

Review 1.  MGUS to myeloma: a mysterious gammopathy of underexplored significance.

Authors:  Madhav V Dhodapkar
Journal:  Blood       Date:  2016-10-13       Impact factor: 22.113

Review 2.  Advances in MGUS diagnosis, risk stratification, and management: introducing myeloma-defining genomic events.

Authors:  Ola Landgren
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2021-12-10

Review 3.  Moving From Cancer Burden to Cancer Genomics for Smoldering Myeloma: A Review.

Authors:  Francesco Maura; Niccolò Bolli; Even H Rustad; Malin Hultcrantz; Nikhil Munshi; Ola Landgren
Journal:  JAMA Oncol       Date:  2020-03-01       Impact factor: 31.777

4.  The spectrum of somatic mutations in monoclonal gammopathy of undetermined significance indicates a less complex genomic landscape than that in multiple myeloma.

Authors:  Aneta Mikulasova; Christopher P Wardell; Alexander Murison; Eileen M Boyle; Graham H Jackson; Jan Smetana; Zuzana Kufova; Ludek Pour; Viera Sandecka; Martina Almasi; Pavla Vsianska; Evzen Gregora; Petr Kuglik; Roman Hajek; Faith E Davies; Gareth J Morgan; Brian A Walker
Journal:  Haematologica       Date:  2017-05-26       Impact factor: 9.941

5.  Biobanking strategy and sample preprocessing for integrative research in monoclonal gammopathies.

Authors:  T Ševčíková; K Growková; Z Kufová; J Filipová; P Vrublová; T Jelínek; Z Kořístek; F Kryukov; E Kryukova; R Hájek
Journal:  J Clin Pathol       Date:  2017-03-30       Impact factor: 3.411

6.  Mutational landscape reflects the biological continuum of plasma cell dyscrasias.

Authors:  A Rossi; M Voigtlaender; S Janjetovic; B Thiele; M Alawi; M März; A Brandt; T Hansen; J Radloff; G Schön; U Hegenbart; S Schönland; C Langer; C Bokemeyer; M Binder
Journal:  Blood Cancer J       Date:  2017-02-24       Impact factor: 11.037

7.  Deciphering the chronology of copy number alterations in Multiple Myeloma.

Authors:  Anil Aktas Samur; Stephane Minvielle; Masood Shammas; Mariateresa Fulciniti; Florence Magrangeas; Paul G Richardson; Philippe Moreau; Michel Attal; Kenneth C Anderson; Giovanni Parmigiani; Hervé Avet-Loiseau; Nikhil C Munshi; Mehmet Kemal Samur
Journal:  Blood Cancer J       Date:  2019-03-26       Impact factor: 11.037

8.  Whole-genome sequencing reveals progressive versus stable myeloma precursor conditions as two distinct entities.

Authors:  Bénedith Oben; Guy Froyen; Kylee H Maclachlan; Daniel Leongamornlert; Federico Abascal; Binbin Zheng-Lin; Venkata Yellapantula; Andriy Derkach; Ellen Geerdens; Benjamin T Diamond; Ingrid Arijs; Brigitte Maes; Kimberly Vanhees; Malin Hultcrantz; Elisabet E Manasanch; Dickran Kazandjian; Alexander Lesokhin; Ahmet Dogan; Yanming Zhang; Aneta Mikulasova; Brian Walker; Gareth Morgan; Peter J Campbell; Ola Landgren; Jean-Luc Rummens; Niccolò Bolli; Francesco Maura
Journal:  Nat Commun       Date:  2021-03-25       Impact factor: 14.919

Review 9.  Designing Evolutionary-based Interception Strategies to Block the Transition from Precursor Phases to Multiple Myeloma.

Authors:  Francesco Maura; Ola Landgren; Gareth J Morgan
Journal:  Clin Cancer Res       Date:  2020-08-05       Impact factor: 13.801

10.  Chromothripsis 18 in multiple myeloma patient with rapid extramedullary relapse.

Authors:  Jan Smetana; Jan Oppelt; Martin Štork; Luděk Pour; Petr Kuglík
Journal:  Mol Cytogenet       Date:  2018-01-18       Impact factor: 2.009

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.